Introduction Aspirin acts as an anti-thrombotic drug by inhibiting platelet cyclooxygenase-1 (COX-1) and blocking the production of thromboxane A2, but it also has off-platelet actions that may limit its effectiveness. Since mice have very marked differences in aspirin pharmacokinetics they cannot be used to explore the effects of low dose aspirin in humans. To address these questions, we developed platelet COX-1 knockout mice (platelet-COX-1 -/-) to recapitulate the effect of low-dose aspirin in humans. Methods and Results. Cox-1 fl/fl mice were paired with Pf4-Cre mice to delete COX-1 in the MK lineage. The absence of COX-1 in platelets was confirmed by Western blot analysis, confocal immunofluorescence microscopy and by analysing the distribution of the COX-1 signal and mass with an highthroughput confocal imaging system. The production of thromboxane B2 (TxB 2 ) induced by collagen, A23187 and the PAR-4 activating peptide in platelet rich plasma and whole blood was significantly decreased in platelet-COX-1 -/-mice. This effect was not further reduced by the addition of aspirin in vitro. Further eicosanomic analysis was performed using LC-MS/MS of samples from untreated and A23187-stimulated whole blood. 11-and 15-hydroxyeicosatetraenoic acid (HETE), alongside TxB 2 formation were inhibited after platelet COX-1 deletion. Production of 12-HETE, coming from 12-lipoxygenase (LOX), and 5-HETE coming from leukocyte 5-LOX, was unchanged in platelet-COX-1 -/-mice. To better dissect the effects of aspirin in vivo, we used a thrombosis model caused by ferric chloride injury in the mouse carotid artery. Platelet COX-1 -/-mice, that recapitulate the effects of low-dose aspirin, formed unstable thrombi that were embolizing before producing a stable vessel occlusion. Interestingly, when a high dose of aspirin (10 mg/kg) was injected into the mice, the thrombus was stable and formed earlier than in the vehicle-treated mice. Conclusions We have produced the first platelet-COX-1 -/-mouse and characterised its phenotype and eicosanomic profile. This model is allowing us to mechanistically dissect the platelet and non-platelet effects of aspirin and so better model the effects of clinically important anti-thrombotic therapy. Purpose When attempting defibrillation in an out-of-hospital paediatric patient, the use of a reduced energy is currently recommended in the resuscitation guidelines due to concerns surrounding potential myocardial damage. The purpose of this pilot study was to investigate the 1st shock success of two different automated external defibrillator (AED) energy protocols and observe the resulting levels of myocardial damage in a paediatric model of cardiac arrest. Method A total of six piglets (10-25 kg) were anaesthetised, instrumented and ventricular fibrillation (VF) was electrically induced. After approximately 15 s of untreated VF, a defibrillation shock was delivered using the selected device in line with Protocol A (adult energy doses of 150J) or Protocol B (paediatric energy doses of 75J). Following successful defibrillation, a 3 min recovery period was allowed for the heart to recover before VF was again induced with a maximum of 20 shocks administered. Blood samples were collected at predefined time-points whilst the animal was under anaesthesia and analysed for cardiac troponin I (cTnI). After the defibrillation phase of the protocol, the animals remained anaesthetised and vital signs monitored for a period of 6 hours with blood samples collected hourly for further analysis. Results A total of 120 shocks were delivered across both protocols with a 100% shockable rhythm detection and 100% first shock success observed in both Protocol A and B. Prior to the induction of VF, Protocol A and B presented with similar initial mean (±SD) levels of cTnI; 0.04 (±0.03) ng/ml (n=3) and 0.03 (±0.02) ng/ml (n=3), respectively. Comparable results of cTnI were also observed upon completion of the defibrillation phase (Shock 20); Protocol A -0.12 (±0.05) ng/ml and Protocol B -0.14 (±0.07) ng/ml. An increase in mean cTnI was detected into the rest period, peaking by 5 hours for both energy protocols. At the 6 hour endpoint of this study, the mean value of cTnI in the blood was reducing for both energy protocols with no statistically significant difference observed between the high and low defibrillation energy groups. Conclusion There was no statistical evidence to suggest that treating the paediatric animals with a higher adult shock energy caused more myocardial damage than a paediatric shock energy. Further investigations are warranted to determine the long term impact on myocardial tissues in a paediatric patient. 10.1136/heartjnl-2017-311726.148 One of the main contributor to atrial arrhythmias (AA) is the activation of the persistent Na channels (Na P ) leading to raised intracellular Ca 2+ concentration ([Ca 2+ ] i ). Incidences of AA exhibit diurnal patterns suggestive of possible correlation between circadian rhythms and atrial electrophysiology. Circadian rhythms are mediated by cellular circadian clocks, made up of transcriptional-translational feedback loops consisting of several genes, in particular Bmal1. So far, the correlation between raised [Ca 2+ ] i induced by activated Na P and Bmal1 rhythmicity is unknown. The aim of this study is to assess the effects of 1)Na P opener, ATXII, Anemonia Sulcata toxin II and 2)raised [Ca 2+ ] i induced by Na P on Bmal1 gene circadian rhythmicity in cultured mouse atrial (HL-1-6) cells and mouse embryonic fibroblasts (MEFs, positive control).
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HL-1-6 were grown in Claycomb medium with 10% FBS, 0.1 mM norepinephrine and 2 mM l-glutamine, whereas, MEFs were maintained in DMEM with 10% FBS. The cells were transduced with Bmal1::luciferase (BMAL1::LUC) probe to determine bioluminescence rhythmicity through long-term bioluminescence recording over several circadian cycles (4-5 days). Cells were serum shocked (2 hours) using 50% FBS to synchronise all cellular clocks. Cells were then incubated in Abstracts Heart 2017;103(Suppl 5):A1-A162 A109
